CDTX

Rezafungin

Treatment of Fungal Infections

Stage (next event)

Expected Date

Phase 3 Topline Data

Q4 2021

Catalyst Info & Data Links

TITLE: Rezafungin for Treatment of Fungal Infections - Phase 3 

  • ClinicalTrial.gov (NCT03667690): Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)


WHAT IS THE NEXT CATALYST EVENT?

  • Topline Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • End of 2021


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • Rezafungin is a novel echinocandin antifungal and the only once-weekly drug candidate being developed for the first-line treatment and prevention of serious invasive fungal infections. Rezafungin has a unique pharmacokinetic profile with a prolonged half-life and front-loaded plasma exposure which, in contrast to all other echinocandins, allows for once-weekly IV therapy for inpatient and outpatient use.

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

NBRV down 16.6% Today - Market Remains Tough on Companies Developing New Antibiotics

Cidara Therapeutics: An Attractive Price For A Niche Opportunity With A High Probability Of Success

AMP Starts Position in Cidara Therapeutics

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon